WO2009022897A3 - Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal - Google Patents
Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal Download PDFInfo
- Publication number
- WO2009022897A3 WO2009022897A3 PCT/MX2008/000104 MX2008000104W WO2009022897A3 WO 2009022897 A3 WO2009022897 A3 WO 2009022897A3 MX 2008000104 W MX2008000104 W MX 2008000104W WO 2009022897 A3 WO2009022897 A3 WO 2009022897A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- organs
- animal
- human
- angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/47—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica sinérgica, útil para inhibir Ia neovascularización (angiogénesis) corneal y retinal, y de otros órganos, en un humano o animal, caracterizada porque comprende, en un vehículo o portador farmacéuticamente aceptable: 60 a 90 % en peso de Suramina, o el equivalente de una de sus sales farmacéuticamente aceptables; y 40 a 10 % en peso de Bevacizumab; en donde dichos porcentajes son con respecto a Ia suma de los pesos de ambos principios activos. Dicha composición farmacéutica sinérgica se presenta bajo Ia forma de una composición inyectable por vía endovenosa, intravítrea o subconjuntival, o bajo Ia forma para Ia administración tópica.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08793787A EP2186529B1 (en) | 2007-08-07 | 2008-08-07 | Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
ES08793787T ES2385121T3 (es) | 2007-08-07 | 2008-08-07 | Composición farmacéutica sinérgica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal, y de otros órganos, en un humano o animal |
DK08793787.6T DK2186529T3 (da) | 2007-08-07 | 2008-08-07 | Anvendelig synergisk og farmaceutisk sammensætning til hæmning af corneal og retinal neovaskularisering (angiogenese), og i andre organer, hos et menneske eller dyr |
CA2736382A CA2736382A1 (en) | 2007-08-07 | 2008-08-07 | Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
AT08793787T ATE551072T1 (de) | 2007-08-07 | 2008-08-07 | Synerge pharmazeutische zusammensetzung zur hemmung von hornhaut- und netzhaut- neovaskularisation (angiogenese) und in anderen organen eines menschen oder tieres |
US12/735,659 US9023350B2 (en) | 2007-08-07 | 2008-08-07 | Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP20070103482 | 2007-08-07 | ||
ARP070103482A AR062239A1 (es) | 2007-08-07 | 2007-08-07 | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009022897A2 WO2009022897A2 (es) | 2009-02-19 |
WO2009022897A3 true WO2009022897A3 (es) | 2009-03-26 |
Family
ID=39929413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2008/000104 WO2009022897A2 (es) | 2007-08-07 | 2008-08-07 | Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal |
Country Status (8)
Country | Link |
---|---|
US (1) | US9023350B2 (es) |
EP (1) | EP2186529B1 (es) |
AR (1) | AR062239A1 (es) |
AT (1) | ATE551072T1 (es) |
CA (1) | CA2736382A1 (es) |
DK (1) | DK2186529T3 (es) |
ES (1) | ES2385121T3 (es) |
WO (1) | WO2009022897A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2796312C (en) * | 2010-05-28 | 2020-11-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
US10296814B1 (en) | 2013-06-27 | 2019-05-21 | Amazon Technologies, Inc. | Automated and periodic updating of item images data store |
US10366306B1 (en) | 2013-09-19 | 2019-07-30 | Amazon Technologies, Inc. | Item identification among item variations |
WO2015185977A1 (en) * | 2014-06-03 | 2015-12-10 | Arturo Solis Herrera | Animal models of corneal angiogenesis and corneal ectatic diseases, methods of producing, and methods of use thereof |
CA3037116A1 (en) * | 2016-10-14 | 2018-04-19 | Novartis Ag | Methods for treating ocular disease using inhibitors of csf-1r |
EP3979985A4 (en) * | 2019-06-07 | 2023-05-03 | Paxmedica, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES |
JP2023541141A (ja) * | 2020-09-04 | 2023-09-28 | ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ | がんを治療するための組み合わせ組成物及び方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006125815A2 (en) * | 2005-05-25 | 2006-11-30 | Nycomed Gmbh | Tetrahydropyridothiophenes for use in the treatment of cancer |
US20070071756A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121320A (en) * | 1997-02-26 | 2000-09-19 | The University Of Kentucky Research Foundation | Combination anti-leukemic therapy by utilizing suramin and biologic response modifiers |
FR2953411B1 (fr) * | 2009-12-03 | 2012-02-03 | Biocodex | Combinaison synergique de composes analgesiques |
-
2007
- 2007-08-07 AR ARP070103482A patent/AR062239A1/es not_active Application Discontinuation
-
2008
- 2008-08-07 ES ES08793787T patent/ES2385121T3/es active Active
- 2008-08-07 DK DK08793787.6T patent/DK2186529T3/da active
- 2008-08-07 AT AT08793787T patent/ATE551072T1/de active
- 2008-08-07 WO PCT/MX2008/000104 patent/WO2009022897A2/es active Application Filing
- 2008-08-07 EP EP08793787A patent/EP2186529B1/en not_active Expired - Fee Related
- 2008-08-07 US US12/735,659 patent/US9023350B2/en active Active
- 2008-08-07 CA CA2736382A patent/CA2736382A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006125815A2 (en) * | 2005-05-25 | 2006-11-30 | Nycomed Gmbh | Tetrahydropyridothiophenes for use in the treatment of cancer |
US20070071756A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
Non-Patent Citations (1)
Title |
---|
HUTSON THOMAS E ET AL: "Targeting growth factor and antiangiogenic pathways in clear-cell renal cellcarcinoma: rationale and ongoing trials", CLINICAL GENITOURINARY CANCER, CANCER INFORMATION GROUP, US, vol. 5, no. 1, 1 December 2006 (2006-12-01), pages s31 - s39, XP008080368, ISSN: 1558-7673 * |
Also Published As
Publication number | Publication date |
---|---|
ES2385121T3 (es) | 2012-07-18 |
US20110076266A1 (en) | 2011-03-31 |
CA2736382A1 (en) | 2009-02-19 |
EP2186529B1 (en) | 2012-03-28 |
EP2186529A2 (en) | 2010-05-19 |
WO2009022897A2 (es) | 2009-02-19 |
AR062239A1 (es) | 2008-10-22 |
US9023350B2 (en) | 2015-05-05 |
DK2186529T3 (da) | 2012-07-16 |
ATE551072T1 (de) | 2012-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009022897A3 (es) | Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal | |
WO2005105067A3 (en) | Aqueous solutions comprising prednisolone and a cyclodextrin derivative | |
WO2007106381A3 (en) | Ophthalmic compositions comprising povidone-iodine | |
JP2010222367A5 (es) | ||
WO2005072745A3 (en) | Aqueous solutions comprising prednisolone and a cyclodextrin derivative | |
WO2006133941A3 (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
NZ594557A (en) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | |
WO2005094799A3 (en) | Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity | |
WO2010123569A3 (en) | Immunonanotherapeutics providing a th1-biased response | |
WO2007048219A3 (en) | Sustained drug release composition | |
WO2007044668A3 (en) | Compstatin and analogs thereof for eye disorders | |
WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
WO2008140052A1 (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
RU2012131251A (ru) | Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз | |
MX2009003750A (es) | Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. | |
WO2009109616A3 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40 | |
WO2007075720A8 (en) | Topical mecamylamine formulations for ocular administration and uses thereof | |
AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
WO2006039252A3 (en) | Compositions and methods for treating ophthalmic diseases | |
JP2009519962A5 (es) | ||
WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
EP4344743A3 (en) | Heterocyclic flavone derivatives, compositions, and methods related thereto | |
MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08793787 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008793787 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12735659 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2736382 Country of ref document: CA |